Tekla Life Sciences Investors (HQL) to Issue Dividend Increase – $0.37 Per Share

Tekla Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Wednesday, May 22nd, Wall Street Journal reports. Stockholders of record on Friday, May 31st will be paid a dividend of 0.37 per share on Friday, June 28th. This represents a $1.48 annualized dividend and a dividend yield of 9.01%. The ex-dividend date is Thursday, May 30th. This is a boost from Tekla Life Sciences Investors’s previous quarterly dividend of $0.33.

Tekla Life Sciences Investors has decreased its dividend payment by an average of 8.1% per year over the last three years.

Shares of NYSE HQL opened at $16.42 on Thursday. Tekla Life Sciences Investors has a 1 year low of $13.95 and a 1 year high of $20.68.

COPYRIGHT VIOLATION NOTICE: “Tekla Life Sciences Investors (HQL) to Issue Dividend Increase – $0.37 Per Share” was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.wkrb13.com/2019/05/23/tekla-life-sciences-investors-hql-to-issue-dividend-increase-0-37-per-share.html.

About Tekla Life Sciences Investors

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

Further Reading: How does inflation affect different investments?

Dividend History for Tekla Life Sciences Investors (NYSE:HQL)

Receive News & Ratings for Tekla Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekla Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.